Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Medical Genetics

The Biology of ML III: Missing Tags and Missorted Enzymes

At a Glance

Mucolipidosis III (ML III) occurs when a missing enzyme prevents the cell from attaching "shipping tags" to its recycling enzymes. Because of this, the enzymes leak into the blood, and waste builds up inside the cell's lysosomes, leading to bone and joint issues in children.

To understand Mucolipidosis III (ML III), it helps to look inside your child’s cells. Every cell has a lysosome, which functions like a recycling center [1]. Its job is to break down waste materials so the cell can stay healthy and clean. In ML III, the process of getting the “recycling workers” (enzymes) to that center is disrupted [1][2].

The “Shipping Tag” Failure

Cells create specialized enzymes to break down waste inside the lysosome. For these enzymes to reach the recycling center, they need a specific shipping label called mannose 6-phosphate (M6P) [3][2].

In ML III, the cell is missing or has a low supply of an enzyme called GlcNAc-phosphotransferase [1][4]. Think of this enzyme as the “labeling machine.” Without it:

  • The shipping tags (M6P) are never attached to the enzymes [1][5].
  • The cell doesn’t know where to send these enzymes, so they are accidentally shipped outside the cell (the extracellular space) [1][2].
  • Because the enzymes are in the blood instead of the lysosome, the recycling center remains empty, and waste materials like glycosaminoglycans (complex sugars) and fats begin to build up inside the cell [2][6].

Subtypes: Alpha/Beta vs. Gamma

The “labeling machine” (GlcNAc-phosphotransferase) is made of three parts: alpha, beta, and gamma subunits [3]. Depending on which part of the machine is broken, ML III is classified into two main subtypes:

ML III Alpha/Beta (GNPTAB Gene)

This subtype occurs when there is a mutation in the GNPTAB gene, which controls the alpha and beta subunits [1][7].

  • The Impact: These subunits form the core “engine” of the labeling machine. Mutations here typically lead to a more significant loss of function [1][8].
  • Bone Remodeling: This subtype is specifically linked to impaired bone remodeling—the constant process where the body breaks down old bone and builds new bone [8]. This can lead to more severe skeletal issues over time [9].

ML III Gamma (GNPTG Gene)

This subtype is caused by a mutation in the GNPTG gene, which controls the gamma subunit [1][7].

  • The Impact: The gamma subunit helps the machine recognize certain specific enzymes [10]. Because the main “engine” (the alpha/beta parts) is still working, there is often more residual activity left [8][11].
  • Clinical Picture: ML III gamma is generally considered a milder form [9]. While these children still experience joint stiffness and physical symptoms, the primary cause is often changes in the cartilage and tendons rather than a major defect in the bone itself [12][8].

Why the Blood Levels are High

You may notice in medical reports that your child has very high levels of lysosomal enzymes in their blood (plasma) [13][2]. This is a direct result of the “shipping tag” failure. Because the enzymes cannot get into the lysosomes, they leak out into the bloodstream in large quantities [2][14]. While these high levels in the blood are used to help diagnose ML III, they also mean the enzymes aren’t where they are needed most—inside the cells [2].

Common questions in this guide

What causes Mucolipidosis III in cells?
ML III is caused by a shortage or absence of an enzyme called GlcNAc-phosphotransferase. Without this enzyme, cells cannot properly tag waste-recycling enzymes, causing waste to build up inside the cell while the useful enzymes leak into the bloodstream.
What is the difference between ML III alpha/beta and gamma?
ML III alpha/beta is caused by a mutation in the GNPTAB gene and typically results in more severe bone remodeling issues. ML III gamma is caused by a GNPTG gene mutation and is generally milder, affecting primarily cartilage and tendons rather than bone structure.
Why are blood enzyme levels high in children with ML III?
Because the cells lack the proper shipping tags to send recycling enzymes into the cell's recycling center, those enzymes leak outside the cell. This causes high levels of lysosomal enzymes to accumulate in the bloodstream, which is a key marker doctors use to diagnose the condition.
What is the role of mannose 6-phosphate in ML III?
Mannose 6-phosphate acts as a shipping label that tells the cell where to send its recycling enzymes. In Mucolipidosis III, the genetic labeling machine is broken, so these tags are never attached, and the enzymes never reach their destination.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Could you explain our child's specific genetic mutation and how it affects the alpha/beta or gamma subunits of the enzyme?
  2. 2.How closely should we be monitoring bone remodeling and bone density given my child's specific subtype?
  3. 3.Are there any clinical trials studying enzyme replacement or gene therapy for the GlcNAc-phosphotransferase pathway that we should keep an eye on?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Case Report: Mucolipidosis II and III Alpha/Beta Caused by Pathogenic Variants in the GNPTAB Gene (Mucolipidosis).

    Mao SJ, Zu YM, Dai YL, Zou CC

    Frontiers in pediatrics 2022; (10()):852701 doi:10.3389/fped.2022.852701.

    PMID: 35463894
  2. 2

    Mucolipidoses Overview: Past, Present, and Future.

    Khan SA, Tomatsu SC

    International journal of molecular sciences 2020; (21(18)) doi:10.3390/ijms21186812.

    PMID: 32957425
  3. 3

    Structures of the mannose-6-phosphate pathway enzyme, GlcNAc-1-phosphotransferase.

    Gorelik A, Illes K, Bui KH, Nagar B

    Proceedings of the National Academy of Sciences of the United States of America 2022; (119(33)):e2203518119 doi:10.1073/pnas.2203518119.

    PMID: 35939698
  4. 4

    GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report.

    Ho CC, Tsung LL, Liu KT, Poon WT

    BMC medical genetics 2018; (19(1)):162 doi:10.1186/s12881-018-0679-5.

    PMID: 30208878
  5. 5

    Multi-omic analysis of a mucolipidosis II neuronal cell model uncovers involvement of pathways related to neurodegeneration and drug metabolism.

    Badenetti L, Yu SH, Colonna MB, et al.

    Molecular genetics and metabolism 2024; (143(3)):108596 doi:10.1016/j.ymgme.2024.108596.

    PMID: 39461112
  6. 6

    Lysosomal Proteome and Secretome Analysis Identifies Missorted Enzymes and Their Nondegraded Substrates in Mucolipidosis III Mouse Cells.

    Di Lorenzo G, Velho RV, Winter D, et al.

    Molecular & cellular proteomics : MCP 2018; (17(8)):1612-1626 doi:10.1074/mcp.RA118.000720.

    PMID: 29773673
  7. 7

    Genetic Testing of a Large Consanguineous Pakistani Family Affected with Mucolipidosis III Gamma Through Next-Generation Sequencing.

    Khan MA, Hussain A, Sher G, et al.

    Genetic testing and molecular biomarkers 2018; (22(9)):541-545 doi:10.1089/gtmb.2018.0123.

    PMID: 30235039
  8. 8

    Pathogenic variants in GNPTAB and GNPTG encoding distinct subunits of GlcNAc-1-phosphotransferase differentially impact bone resorption in patients with mucolipidosis type II and III.

    Di Lorenzo G, Westermann LM, Yorgan TA, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(12)):2369-2377 doi:10.1038/s41436-021-01285-9.

    PMID: 34341521
  9. 9

    Clinical Characterization of Mucolipidoses II and III: A Multicenter Study.

    Alegra T, Sperb-Ludwig F, Guarany NR, et al.

    Journal of pediatric genetics 2019; (8(4)):198-204 doi:10.1055/s-0039-1697605.

    PMID: 31687257
  10. 10

    Enzyme-specific differences in mannose phosphorylation between GlcNAc-1-phosphotransferase αβ and γ subunit deficient zebrafish support cathepsin proteases as early mediators of mucolipidosis pathology.

    Flanagan-Steet H, Matheny C, Petrey A, et al.

    Biochimica et biophysica acta 2016; (1860(9)):1845-53.

    PMID: 27241848
  11. 11

    Humoral immune response in adult Brazilian patients with Mucolipidosis III gamma.

    Sperb-Ludwig F, Alegra T, Velho RV, et al.

    Genetics and molecular biology 2019; (42(3)):571-573 doi:10.1590/1678-4685-GMB-2018-0246.

    PMID: 31188938
  12. 12

    Imbalanced cellular metabolism compromises cartilage homeostasis and joint function in a mouse model of mucolipidosis type III gamma.

    Westermann LM, Fleischhauer L, Vogel J, et al.

    Disease models & mechanisms 2020; (13(11)) doi:10.1242/dmm.046425.

    PMID: 33023972
  13. 13

    Mucolipidosis III GNPTG Missense Mutations Cause Misfolding of the γ Subunit of GlcNAc-1-Phosphotransferase.

    van Meel E, Kornfeld S

    Human mutation 2016; (37(7)):623-6 doi:10.1002/humu.22993.

    PMID: 27038293
  14. 14

    Mucolipidosis type II and III: clinical spectrum, genetic landscape, and longitudinal outcomes in a pediatric cohort with six novel mutations.

    Erdem F, Canda E, Yazıcı H, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2025; (38(12)):1286-1298 doi:10.1515/jpem-2025-0352.

    PMID: 41064848

This page explains the biology and genetics of Mucolipidosis III for educational purposes only. Always consult a pediatric geneticist or metabolic specialist to understand your child's specific genetic subtype and care plan.

Get notified when new evidence is published on Mucolipidosis type III.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.